Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study

Bertisch, Barbara; Franceschi, Silvia; Lise, Mauro; Vernazza, Pietro; Keiser, Olivia; Schöni-Affolter, Franziska; Bouchardy, Christine; Dehler, Silvia; Levi, Fabio; Jundt, Gernot; Ess, Silvia; Pawlita, Michael; Kovari, Helen; Wandeler, Gilles; Calmy, Alexandra; Cavassini, Matthias; Stöckle, Marcel; Clifford, Gary (2013). Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. American journal of epidemiology, 178(6), pp. 877-884. Oxford University Press 10.1093/aje/kwt153

[img] Text
Bertisch AmJEpidemiol 2013.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (207kB) | Request a copy
[img] Text
Bertisch AmJEpidemiol 2013_manuscript.docx - Accepted Version
Available under License Publisher holds Copyright.

Download (86kB)

Although persons infected with human immunodeficiency virus (HIV), particularly men who have sex with men, are at excess risk for anal cancer, it has been difficult to disentangle the influences of anal exposure to human papillomavirus (HPV) infection, immunodeficiency, and combined antiretroviral therapy. A case-control study that included 59 anal cancer cases and 295 individually matched controls was nested in the Swiss HIV Cohort Study (1988-2011). In a subset of 41 cases and 114 controls, HPV antibodies were tested. A majority of anal cancer cases (73%) were men who have sex with men. Current smoking was significantly associated with anal cancer (odds ratio (OR) = 2.59, 95% confidence interval (CI): 1.25, 5.34), as were antibodies against L1 (OR = 4.52, 95% CI: 2.00, 10.20) and E6 (OR = ∞, 95% CI: 4.64, ∞) of HPV16, as well as low CD4+ cell counts, whether measured at nadir (OR per 100-cell/μL decrease = 1.53, 95% CI: 1.18, 2.00) or at cancer diagnosis (OR per 100-cell/μL decrease = 1.24, 95% CI: 1.08, 1.42). However, the influence of CD4+ cell counts appeared to be strongest 6-7 years prior to anal cancer diagnosis (OR for <200 vs. ≥500 cells/μL = 14.0, 95% CI: 3.85, 50.9). Smoking cessation and avoidance of even moderate levels of immunosuppression appear to be important in reducing long-term anal cancer risks.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Keiser, Olivia; Schöni-Affolter, Franziska and Wandeler, Gilles

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0002-9262

Publisher:

Oxford University Press

Language:

English

Submitter:

Beatrice Minder Wyssmann

Date Deposited:

20 Mar 2014 11:14

Last Modified:

25 Nov 2016 09:09

Publisher DOI:

10.1093/aje/kwt153

PubMed ID:

23900553

Uncontrolled Keywords:

HIV, anal cancer, case-control study, human papillomavirus, immunodeficiency

BORIS DOI:

10.7892/boris.44373

URI:

https://boris.unibe.ch/id/eprint/44373

Actions (login required)

Edit item Edit item
Provide Feedback